Bazedoxifene - CAS 198481-32-2
Catalog number:
198481-32-2
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Targets:
Estrogen Receptor/ERR
Description:
Bazedoxifene is a selective estrogen receptor modulator (SERM) currently in development for osteoporosis prevention and treatment.
Publictions citing BOC Sciences Products
  • >> More
Purity:
0.98
Synonyms:
Viviant; Conbriza; Aprela
MSDS:
Inquire
1.Bazedoxifene and conjugated equine estrogen: A combination product for the management of vasomotor symptoms and osteoporosis prevention associated with menopause.
Umland EM1, Karel L2, Santoro N3. Pharmacotherapy. 2016 Mar 29. doi: 10.1002/phar.1749. [Epub ahead of print]
Bazedoxifene (BZA), a third generation selective estrogen receptor modulator (SERM), has been combined with conjugated equine estrogen (CE) to create a tissue selective estrogen complex (TSEC) for the management of vasomotor symptoms (VMS) and the prevention of osteoporosis (OP) associated with menopause. Both of these outcomes of menopause contribute to significant negative effects on quality of life and increases in utilization of healthcare resources and dollars. Current treatment modalities for VMS and OP include estrogen therapy that requires the use of progestin in women who have a uterus to reduce the risk of endometrial hyperplasia and resultant cancer. However, progestin use results in nuisance bleeding as well as a further increased risk of breast cancer when combined with estrogen. And while SERMs can be used to prevent OP, their use alone has been shown to increase hot flashes. The combination of BZA and CE does not require progestin treatment with CE as the BZA component acts as an antagonist on endometrial tissue.
2.Bazedoxifene, a new orphan drug for the treatment of bleeding in hereditary haemorrhagic telangiectasia.
Zarrabeitia R, Ojeda-Fernandez L, Recio L, Bernabéu C, Parra JA, Albiñana V, Botella LM1. Thromb Haemost. 2016 Jan 28;115(6). [Epub ahead of print]
Hereditary haemorrhagic telangiectasia (HHT), or Rendu-Osler-Weber syndrome, is a dominant genetic vascular disorder. In HHT, blood vessels are weak and prone to bleeding, leading to epistaxis and anaemia, severely affecting patients' quality of life. Development of vascular malformations in HHT patients is originated mainly by mutations in ACVRL1/ALK1 (activin receptor-like kinase type I) or Endoglin (ENG) genes. These genes encode proteins of the TGF-β signalling pathway in endothelial cells, controlling angiogenesis. Haploinsufficiency of these proteins is the basis of HHT pathogenicity. It was our objective to study the efficiency of Bazedoxifene, a selective estrogen receptor modulator (SERM) in HHT, looking for a decrease in epistaxis, and understanding the underlying molecular mechanism. Plasma samples of five HHT patients were collected before, and after 1 and 3 months of Bazedoxifene treatment. ENG and ALK1 expression in activated mononuclear cells derived from blood, as well as VEGF plasma levels, were measured.
3.Efficacy and tolerability of bazedoxifene in Mexican women with osteoporosis: a subgroup analysis of a randomized phase 3 trial.
Palacios S1, Williams R, Mirkin S, Pan K, Arias L, Komm BS. Menopause. 2016 Apr 7. [Epub ahead of print]
OBJECTIVE: Bazedoxifene (BZA) is a selective estrogen receptor modulator that reduces fracture risk and bone turnover in postmenopausal women with osteoporosis. This analysis evaluated BZA's effects on bone mineral density (BMD) and bone turnover in Mexican women with osteoporosis from the global pivotal trial (Study Evaluating Bazedoxifene Acetate in Osteoporosis in Postmenopausal Women).
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Estrogen Receptor/ERR Products


CAS 50-27-1 Estriol

Estriol
(CAS: 50-27-1)

Estriol is a metabolite of 17β-estradiol with much lower biological activity. It is the primary estrogen found in the urine. Large quantities of estriol and est...

CAS 313-06-4 Estradiol Cypionate

Estradiol Cypionate
(CAS: 313-06-4)

Estradiol cypionate is the 17 β-cyclopentylpropinate ester of estradiol, which inhibits ET-1 synthesis via estrogen receptor.

CAS 725247-18-7 XCT 790

XCT 790
(CAS: 725247-18-7)

XCT-790 is a potent, selective ERRα antagonist/inverse agonist (IC50 = ~400 nM), displaying no antagonist activity at ERRγ or ERα at concentrations below 10 μM.

CAS 50-50-0 Estradiol Benzoate

Estradiol Benzoate
(CAS: 50-50-0)

Estradiol benzoate is an estradiol analog which binds to the human, murine and chicken ERα with IC50 of 22-28 nM.

CAS 182133-25-1 Arzoxifene

Arzoxifene
(CAS: 182133-25-1)

Arzoxifene, also known as LY353381, a synthetic aromatic derivative with anti-estrogenic properties, displays greater bioavailability and higher anti-estrogenic...

CAS 50-41-9 Clomifene citrate

Clomifene citrate
(CAS: 50-41-9)

Clomifene Citrate is a selective estrogen receptor modulator used in the treatment of ovulation induction. It is used to treat breast cancer for its antineoplas...

AZD9496 maleate
(CAS: 1639042-28-6)

AZD9496 maleate is potent downregulator of estrogen receptor in breast carcinoma cells and also antagonise ERα with good oral pharmacokinetic properties. It is ...

CAS 190791-29-8 Lasofoxifene tartrate

Lasofoxifene tartrate
(CAS: 190791-29-8)

Lasofoxifene tartrate is the tartrate salt form of Lasofoxifene. Lasofoxifene is a third-generation selective estrogen receptor modulators (SERMs).

CAS 440122-66-7 WAY-200070

WAY-200070
(CAS: 440122-66-7)

WAY-200070 is a selective estrogen receptor β (ERRβ) agonist (IC50= 2.3 nM) that exhibit 68-fold selectivity over ERα (EC50= 155 nM for ERα).

GDC-0810 (ARN-810)
(CAS: 1365888-06-7)

GDC-0810, also known as ARN-810 and RG6046, an orally bioavailable Selective Estrogen Receptor Degrader (SERD) that demonstrates robust activity in tamoxifen-re...

CAS 15690-57-0 trans-Clomiphene

trans-Clomiphene
(CAS: 15690-57-0)

Trans-Clomiphene, a stilbenes derivative, has been found to be an estrogen receptor antagonist as well as testosterone agonist. It has been developed for hypogo...

CAS 1845-11-0 Nafoxidine

Nafoxidine
(CAS: 1845-11-0)

Nafoxidine, a triphenylethylene nonsteroidal agent, is a partial estrogen antagonist.

CAS 245124-69-0 Pipendoxifene hydrochloride

Pipendoxifene hydrochloride
(CAS: 245124-69-0)

Pipendoxifene hydrochloride is the hydrochloride salt of Pipendoxifene which

Phenethipylone
(CAS: 63676-25-5)

Phenethipylone is a selective estrogen receptor modulator. It is a raloxifene analog.

CAS 343248-86-2 ERA63

ERA63
(CAS: 343248-86-2)

A selective agonist of estrogen receptor α

AZD9496
(CAS: 1639042-08-2)

AZD9496 is a potent and orally bioavailable selective estrogen receptor downregulator and antagonist. AZD9496 can induce ERα degradation in breast cancer cell l...

CAS 89778-27-8 PF-03758309

PF-03758309
(CAS: 89778-27-8)

PF-03758309 is a potent, ATP-competitive, pyrrolopyrazole inhibitor of PAK4 with IC50 of 1.3 nM.

CAS 979-32-8 Estradiol valerate

Estradiol valerate
(CAS: 979-32-8)

Estradiol valerate is a synthetic ester, specifically the 17-pentanoyl ester, of the natural estrogen, 17β-estradiol. It was introduced in the 1950s, and a...

CAS 112093-28-4 Endoxifen

Endoxifen
(CAS: 112093-28-4)

Endoxifen, a significant metamolite of Tamoxifen, is a regulator of estrogen receptor and could be effective in the treatment of estrogen-dependent breast cance...

CAS 7280-37-7 Estropipate

Estropipate
(CAS: 7280-37-7)

Estropipate is an estrogen receptor agonist used in post-menopausal women for hormonal replacement therapy, with benefits to improved cognition and prevention o...

Chemical Structure

CAS 198481-32-2 Bazedoxifene

Quick Inquiry

Verification code

Featured Items